SK bioscience (302440.KS) Earnings Analysis
SK bioscience (302440.KS) next reports earnings on 2026-07-24, consensus EPS -340.68 KRW. Last quarter (2025-07-31) it beat with EPS -210.00075 KRW vs -372.19 KRW est (+43.6%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -32.10.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 302440.KS next report earnings?
| Next earnings date | 2026-07-24 |
|---|---|
| Consensus EPS estimate | -340.68 KRW |
| Revenue estimate | 180.00B |
302440.KS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-07-31 | -210.00075 KRW | -372.19 KRW | +43.6% | Beat |
| 2025-02-05 | -82.16139 KRW | -412.97 KRW | +80.1% | Beat |
| 2024-10-24 | -290 KRW | -131.68 KRW | -120.2% | Miss |
| 2024-07-31 | -148 KRW | -257.43 KRW | +42.5% | Beat |
Beat rate: 3/4 (75%) over reported quarters with consensus data.
302440.KS valuation and analyst view
| Trailing P/E | -32.10 |
|---|---|
| Trailing EPS | -1,045.04381 KRW |
| Price / book | 1.49 |
| Dividend yield | 0.00% |
| Market cap | 2569.45B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is SK bioscience (302440.KS)'s next earnings date?
SK bioscience is next scheduled to report on 2026-07-24, with a consensus EPS estimate of -340.68 KRW and revenue estimate of 180.00B.
Did 302440.KS beat earnings last quarter?
In its 2025-07-31 report, 302440.KS posted EPS of -210.00075 KRW versus a -372.19 KRW estimate — a beat of 43.6%.
What is 302440.KS's earnings track record?
Over the last 4 reported quarters with consensus data, 302440.KS beat estimates 3 times (75%).
What is 302440.KS's current P/E ratio and EPS?
302440.KS trades at a trailing P/E of -32.10 on trailing EPS of -1045.0438068203614 KRW.
What do analysts rate 302440.KS?
302440.KS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.